A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease

Clinical Trials

Volumn 8, Issue 1, 2011, Pages 5-14

  Zhang, Richard Y ^a   Leon, Andrew C ^b   Chuang Stein, Christy ^a   Romano, Steven J ^a  

^a PFIZER INC   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOOTROPIC AGENT; PLACEBO;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITION; HUMAN; MONTE CARLO METHOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANDOMIZED START DESIGN; RATING SCALE; RESEARCH SUBJECT; SAMPLE SIZE;

ALZHEIMER DISEASE; BIOMARKERS, PHARMACOLOGICAL; COGNITION; DISEASE PROGRESSION; DRUGS, INVESTIGATIONAL; HUMANS; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 79951908346     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510392255     Document Type: Article

References (31)

1. Alzheimer's Association. 2007 Alzheimer disease facts and figure. Alzheimer's Association, 2007.
2. Leber P. Guidelines for the Clinical Evaluation of Antidementia Drugs. First Draft. Division of Neuropharmacological Drug Products, FDA, Rockville, MD, 1990.
3. Clinicaltrials.gov, 29 November 2010, http://www.clinicaltrial.gov/ct2/ search
4. Salloway S., Sperling R., Gilman S., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009 ; 73: 2061-70.
5. Stern RG, Mohs RC, Davidson M., et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994 ; 151: 390-96. (Pubitemid 24081459)
6. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA Modelling mini mental state examination changes in Alzheimer's disease. Stat Med 2000 ; 19: 1607-16. (Pubitemid 30346250)
7. Katz R. FDA: Why divergence of slopes between placebo and active treatment alone cannot substantiate disease-modifying effects? Presentation, AAPS Workshop, Arlington, VA, 2008.
8. Leber P. Slowing the progression of Alzheimer disease: methodological issues. Alzheimer Dis Assoc Disord 1997 ; 11: S10-21.
9. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004 ; 61: 561-66.
10. Olanow CW, Rascol O., Hauser R., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. NEJM 2009 ; 361: 1268-78.
11. McDermont M. Design and analysis options for demonstrating disease-modifying effects: general statistical considerations. Presentation, AAPS Workshop, 2008.
12. Siddiqui O. Endpoints and analysis to discern disease-modifying effects for delayed-start design. Presentation, AAPS Workshop, 2008.
13. D'Agostino Sr RB The delayed-start study design. NEJM 2009 ; 361: 1304-06.
14. Mani RB The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 2004 ; 23: 305-14. (Pubitemid 38100643)
15. Mohs RC, Kawas C., Carrillo MC Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimers Dement 2006 ; 2: 131-39. (Pubitemid 43843103)
16. Cummings JL Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement 2006 ; 2: 263-71. (Pubitemid 44524773)
17. Katz R. FDA: Evidentiary standards for drug development and approval. NeuroRx 2004 ; 1: 307-16. (Pubitemid 46589359)
18. Sampaio C. Common difficulties in the clinical development of Alzheimer disease medicines. In: ISCTM Autumn Meeting, Nashville, USA, 2008.
19. Mani RB Establishing claims for long term therapeutic benefit for treatment of Alzheimer's disease, including disease progression: a US regulatory perspective. In: ISCTM Autumn Meeting, Nashville, USA, 2008.
20. Aricept [Package Insert], Eisai Inc, Woodcliff lake, NJ, 2010.
21. Exelon [Package Insert]. Novartis Pharmaceuticals Corporation, East hanover, NJ, 2006.
22. Reminyl [Package Insert]. Janssen Pharmaceutical, Inc, Titusville, NJ, 2002.
23. Data on file, Pfizer Inc, 2008.
24. McDermott MP, Hall WJ, Oakes D., Eberly S. Design and analysis of two-period studies of potentially disease-modifying treatments. Control Clin Trials 2002 ; 23: 635B - 49.
25. Doody RS, Geldmacher DS, Gordon B. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001 ; 58: 427-33. (Pubitemid 32217459)
26. Winblad K., Engedal H., Soininen F., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 ; 57: 489-95.
27. Vellas B., Andrieu S., Sampaio C., Wilcock G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2007 ; 6: 56-62. (Pubitemid 44880273)
28. Fitzmaurice G., Laird N., Ware J. Applied Longitudinal Analysis (1st edn). John Wiley and Sons, Hoboken, NJ, 2004.
29. Heyting A., Tolboom Jtbm, Essers JGA. Statistical handling of drop-outs in longitudinal clinical trials. Stat Med 1992 ; 11: 2043-61. (Pubitemid 23066838)
30. Leon AC, Demirtas H., Hedeker D. Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial. Clin Trials 2007 ; 4: 540-47. (Pubitemid 350189877)
31. Jones RW, Schwam E., Wilkinson D., et al. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis Assoc Disord 2009 ; 23: 357-64.